PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Por um escritor misterioso

Last updated 04 fevereiro 2025

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statin Toxicity Circulation Research

Genetic and immunologic susceptibility to statin-related myopathy.

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Myopathy with statin–fibrate combination therapy: clinical considerations

Myopathy with statin-fibrate combination therapy: clinical considerations - Document - Gale OneFile: Health and Medicine

Full article: Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management

Considerations in the Approach to Appropriate Statin Selection

Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016

Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review

Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. - Abstract - Europe PMC

PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Recomendado para você